Study With [225Ac]Ac-FL-020 in mCRPC Participants
Phase 1
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: [225Ac]Ac-FL-020Drug: Blood samples for PKDrug: [111In]In-FL-020Procedure: Blood and urine samples collectionProcedure: SPECT/CT images
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Full-Life Technologies GmbH
- Target Recruit Count
- 35
- Registration Number
- NCT06492122
- Locations
- 🇺🇸
University of Stanford, Stanford, California, United States
🇦🇺Princess Alexandra Hospital, Brisbane, Australia
🇺🇸City of Hope Medical Center, Duarte, California, United States
© Copyright 2025. All Rights Reserved by MedPath